Bryan K. Tolliver

Title
InstitutionMedical University of South Carolina
DepartmentPsychiatry and Behavioral Sciences
AddressP.O. Box MSC 861
RN 120
125 Doughty St.
Phone843-792-4869
Fax843-792-3982
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Tolliver's clinical and research interests are focused on understanding psychiatric comorbidity and on development of improved medication treatments for bipolar disorders and co-occurring substance use disorders. His research has been supported by the National Institute on Drug Abuse (NIDA) and the National Institute of Alcohol Abuse and Alcoholism (NIAAA).

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Prisciandaro JJ, Mellick W, Squeglia LM, Hix S, Arnold L, Tolliver BK, Prisciandaro JJ, Mellick W, Squeglia LM, Hix S, Arnold L, Tolliver BK. Results from a randomized, double-blind, placebo-controlled, crossover, multimodal-MRI pilot study of gabapentin for co-occurring bipolar and cannabis use disorders. Addict Biol. 2022 01; 27(1):e13085. PMID: 34390300; PMCID: PMC9104469.
      Citations:    
    2. Mellick W, Prisciandaro JJ, Brenner H, Brown D, Tolliver BK, Mellick W, Prisciandaro JJ, Brenner H, Brown D, Tolliver BK. A Multimethod Examination of Sensitivity to Reward and Sensitivity to Punishment in Bipolar Disorder and Alcohol Dependence: Results from a 2 ? 2 Factorial Design. Psychopathology. 2021; 54(2):70-77. PMID: 33596587; PMCID: PMC8058164.
      Citations:    
    3. Prisciandaro JJ, Brown DG, Brady KT, Tolliver BK, Prisciandaro JJ, Brown DG, Brady KT, Tolliver BK. Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial. Psychiatry Res. 2021 Jan; 295:112904. PMID: 32456807.
      Citations:    
    4. Mellick W, Tolliver BK, Brenner H, Prisciandaro JJ, Mellick W, Tolliver BK, Brenner H, Prisciandaro JJ. Delay discounting and reward sensitivity in a 2 ? 2 study of bipolar disorder and alcohol dependence. Addiction. 2019 08; 114(8):1369-1378. PMID: 30927381; PMCID: PMC6626565.
      Citations:    
    5. Prisciandaro JJ, Mellick W, Mitaro E, Tolliver BK, Prisciandaro JJ, Mellick W, Mitaro E, Tolliver BK. An evaluation of the impact of co-occurring anxiety and substance use disorder on bipolar disorder illness outcomes in STEP-BD. J Affect Disord. 2019 03 01; 246:794-799. PMID: 30623826; PMCID: PMC6563327.
      Citations:    
    6. Prisciandaro JJ, Tolliver BK, DeSantis SM, Prisciandaro JJ, Tolliver BK, DeSantis SM. Identification and initial validation of empirically derived bipolar symptom states from a large longitudinal dataset: an application of hidden Markov modeling to the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study. Psychol Med. 2019 05; 49(7):1102-1108. PMID: 30153871; PMCID: PMC7160825.
      Citations:    
    7. Prisciandaro JJ, Tolliver BK, Prescot AP, Brenner HM, Renshaw PF, Brown TR, Anton RF, Prisciandaro JJ, Tolliver BK, Prescot AP, Brenner HM, Renshaw PF, Brown TR, Anton RF. Unique prefrontal GABA and glutamate disturbances in co-occurring bipolar disorder and alcohol dependence. Transl Psychiatry. 2017 07 04; 7(7):e1163. PMID: 28675386; PMCID: PMC5538121.
      Citations:    
    8. Prisciandaro JJ, Tolliver BK, Prisciandaro JJ, Tolliver BK. An item response theory evaluation of the young mania rating scale and the montgomery-asberg depression rating scale in the systematic treatment enhancement program for bipolar disorder (STEP-BD). J Affect Disord. 2016 Nov 15; 205:73-80. PMID: 27420134; PMCID: PMC5048523.
      Citations:    
    9. Marriott BP, Hibbeln JR, Killeen TK, Magruder KM, Holes-Lewis K, Tolliver BK, Turner TH, Marriott BP, Hibbeln JR, Killeen TK, Magruder KM, Holes-Lewis K, Tolliver BK, Turner TH, BRAVO Group. Design and methods for the Better Resiliency Among Veterans and non-Veterans with Omega-3's (BRAVO) study: A double blind, placebo-controlled trial of omega-3 fatty acid supplementation among adult individuals at risk of suicide. Contemp Clin Trials. 2016 Mar; 47:325-33. PMID: 26855120.
      Citations:    
    10. Tolliver BK, Anton RF, Tolliver BK, Anton RF. Assessment and treatment of mood disorders in the context of substance abuse. Dialogues Clin Neurosci. 2015 Jun; 17(2):181-90. PMID: 26246792; PMCID: PMC4518701.
      Citations:    
    11. Prisciandaro JJ, Tolliver BK, Prisciandaro JJ, Tolliver BK. Evidence for the continuous latent structure of mania and depression in out-patients with bipolar disorder: results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Psychol Med. 2015; 45(12):2595-603. PMID: 25881582; PMCID: PMC4751879.
      Citations:    
    12. Saladin ME, Santa Ana EJ, LaRowe SD, Simpson AN, Tolliver BK, Price KL, McRae-Clark AL, Brady KT, Saladin ME, Santa Ana EJ, LaRowe SD, Simpson AN, Tolliver BK, Price KL, McRae-Clark AL, Brady KT. Does alexithymia explain variation in cue-elicited craving reported by methamphetamine-dependent individuals? Am J Addict. 2012 Mar-Apr; 21(2):130-5. PMID: 22332856; PMCID: PMC3281564.
      Citations:    
    13. Tolliver BK, Desantis SM, Brown DG, Prisciandaro JJ, Brady KT, Tolliver BK, Desantis SM, Brown DG, Prisciandaro JJ, Brady KT. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2012 Feb; 14(1):54-63. PMID: 22329472.
      Citations:    
    14. Orr RK, Hoehn JL, Col NF, Tolliver BK, Price KL, Baker NL, LaRowe SD, Simpson AN, McRae-Clark AL, Saladin ME, DeSantis SM, Chapman E, Garrett M, Brady KT. Impaired cognitive performance in subjects with methamphetamine dependence during exposure to neutral versus methamphetamine-related cues. Am J Drug Alcohol Abuse. 2012 May; 38(3):251-9. PMID: 22257306.
      Citations:    
    15. Prisciandaro JJ, DeSantis SM, Chiuzan C, Brown DG, Brady KT, Tolliver BK, Prisciandaro JJ, DeSantis SM, Chiuzan C, Brown DG, Brady KT, Tolliver BK. Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. Alcohol Clin Exp Res. 2012 Mar; 36(3):490-6. PMID: 21933201; PMCID: PMC3248624.
      Citations:    
    16. Orr RK, Hoehn JL, Col NF, Price KL, DeSantis SM, Simpson AN, Tolliver BK, McRae-Clark AL, Saladin ME, Baker NL, Wagner MT, Brady KT. The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina. Am J Addict. 2011 Sep-Oct; 20(5):447-55. PMID: 21838844; PMCID: PMC3603567.
      Citations:    
    17. Prisciandaro JJ, Brown DG, Brady KT, Tolliver BK, Prisciandaro JJ, Brown DG, Brady KT, Tolliver BK. Comorbid anxiety disorders and baseline medication regimens predict clinical outcomes in individuals with co-occurring bipolar disorder and alcohol dependence: Results of a randomized controlled trial. Psychiatry Res. 2011 Aug 15; 188(3):361-5. PMID: 21641663; PMCID: PMC4750381.
      Citations:    
    18. Prisciandaro JJ, Rembold J, Brown DG, Brady KT, Tolliver BK, Prisciandaro JJ, Rembold J, Brown DG, Brady KT, Tolliver BK. Predictors of clinical trial dropout in individuals with co-occurring bipolar disorder and alcohol dependence. Drug Alcohol Depend. 2011 Nov 01; 118(2-3):493-6. PMID: 21549529; PMCID: PMC4745117.
      Citations:    
    19. Brady KT, Gray KM, Tolliver BK, Brady KT, Gray KM, Tolliver BK. Cognitive enhancers in the treatment of substance use disorders: clinical evidence. Pharmacol Biochem Behav. 2011 Aug; 99(2):285-94. PMID: 21557964; PMCID: PMC3114106.
      Citations:    
    20. Gao K, Chan PK, Verduin ML, Kemp DE, Tolliver BK, Ganocy SJ, Bilali S, Brady KT, Findling RL, Calabrese JR, Gao K, Chan PK, Verduin ML, Kemp DE, Tolliver BK, Ganocy SJ, Bilali S, Brady KT, Findling RL, Calabrese JR. Independent predictors for lifetime and recent substance use disorders in patients with rapid-cycling bipolar disorder: focus on anxiety disorders. Am J Addict. 2010 Sep-Oct; 19(5):440-9. PMID: 20716307; PMCID: PMC2924768.
      Citations:    
    21. Price KL, Saladin ME, Baker NL, Tolliver BK, DeSantis SM, McRae-Clark AL, Brady KT, Price KL, Saladin ME, Baker NL, Tolliver BK, DeSantis SM, McRae-Clark AL, Brady KT. Extinction of drug cue reactivity in methamphetamine-dependent individuals. Behav Res Ther. 2010 Sep; 48(9):860-5. PMID: 20538262; PMCID: PMC2914141.
      Citations:    
    22. Tolliver BK, McRae-Clark AL, Saladin M, Price KL, Simpson AN, DeSantis SM, Baker NL, Brady KT, Tolliver BK, McRae-Clark AL, Saladin M, Price KL, Simpson AN, DeSantis SM, Baker NL, Brady KT. Determinants of cue-elicited craving and physiologic reactivity in methamphetamine-dependent subjects in the laboratory. Am J Drug Alcohol Abuse. 2010 Mar; 36(2):106-13. PMID: 20337507.
      Citations:    
    23. Hartwell KJ, Tolliver BK, Brady KT, Hartwell KJ, Tolliver BK, Brady KT. Biologic Commonalities between Mental Illness and Addiction. Prim psychiatry. 2009 Aug 01; 16(8):33-39. PMID: 26030747; PMCID: PMC3623011.
      Citations:    
    24. Gao K, Tolliver BK, Kemp DE, Ganocy SJ, Bilali S, Brady KL, Findling RL, Calabrese JR, Gao K, Tolliver BK, Kemp DE, Ganocy SJ, Bilali S, Brady KL, Findling RL, Calabrese JR. Correlates of historical suicide attempt in rapid-cycling bipolar disorder: a cross-sectional assessment. J Clin Psychiatry. 2009 Jul; 70(7):1032-40. PMID: 19653978; PMCID: PMC3457055.
      Citations:    
    25. Tolliver BK, McRae AL, Verduin ML, Anderson SJ, Brady KT, Tolliver BK, McRae AL, Verduin ML, Anderson SJ, Brady KT. Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: a case series. J Clin Psychopharmacol. 2008 Aug; 28(4):464-7. PMID: 18626281.
      Citations:    
    26. Gao K, Verduin ML, Kemp DE, Tolliver BK, Ganocy SJ, Elhaj O, Bilali S, Brady KT, Findling RL, Calabrese JR, Gao K, Verduin ML, Kemp DE, Tolliver BK, Ganocy SJ, Elhaj O, Bilali S, Brady KT, Findling RL, Calabrese JR. Clinical correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: a subtype comparison from baseline data of 2 randomized, placebo-controlled trials. J Clin Psychiatry. 2008 Jul; 69(7):1057-63. PMID: 18588360; PMCID: PMC4285700.
      Citations:    
    27. Gao K, Tolliver BK, Kemp DE, Verduin ML, Ganocy SJ, Bilali S, Brady KT, Shim SS, Findling RL, Calabrese JR, Gao K, Tolliver BK, Kemp DE, Verduin ML, Ganocy SJ, Bilali S, Brady KT, Shim SS, Findling RL, Calabrese JR. Differential interactions between comorbid anxiety disorders and substance use disorder in rapid cycling bipolar I or II disorder. J Affect Disord. 2008 Sep; 110(1-2):167-73. PMID: 18234350; PMCID: PMC2561239.
      Citations:    
    28. Sullivan MA, Birkmayer F, Boyarsky BK, Frances RJ, Fromson JA, Galanter M, Levin FR, Lewis C, Nace EP, Suchinsky RT, Tamerin JS, Tolliver B, Westermeyer J, Sullivan MA, Birkmayer F, Boyarsky BK, Frances RJ, Fromson JA, Galanter M, Levin FR, Lewis C, Nace EP, Suchinsky RT, Tamerin JS, Tolliver B, Westermeyer J. Uses of coercion in addiction treatment: clinical aspects. Am J Addict. 2008 Jan-Feb; 17(1):36-47. PMID: 18214721.
      Citations:    
    29. Brady KT, Verduin ML, Tolliver BK, Brady KT, Verduin ML, Tolliver BK. Treatment of patients comorbid for addiction and other psychiatric disorders. Curr Psychiatry Rep. 2007 Oct; 9(5):374-80. PMID: 17915076.
      Citations:    
    30. Brady KT, Tolliver BK, Verduin ML, Brady KT, Tolliver BK, Verduin ML. Alcohol use and anxiety: diagnostic and management issues. Am J Psychiatry. 2007 Feb; 164(2):217-21; quiz 372. PMID: 17267782.
      Citations:    
    31. Reid MS, Ho LB, Hsu K, Fox L, Tolliver BK, Adams JU, Franco A, Berger SP, Reid MS, Ho LB, Hsu K, Fox L, Tolliver BK, Adams JU, Franco A, Berger SP. Evidence for the involvement of cyclooxygenase activity in the development of cocaine sensitization. Pharmacol Biochem Behav. 2002 Jan-Feb; 71(1-2):37-54. PMID: 11812506.
      Citations: 5     Fields:    Translation:Animals
    32. Orr RK, Hoehn JL, Col NF, Tolliver BK, Sganga MW, Sharp FR. Suppression of c-fos induction in the nucleus accumbens prevents acquisition but not expression of morphine-conditioned place preference. Eur J Neurosci. 2000 Sep; 12(9):3399-406. PMID: 10998122.
      Citations: 11     Fields:    Translation:Animals
    33. Tomitaka S, Tomitaka M, Tolliver BK, Sharp FR, Tomitaka S, Tomitaka M, Tolliver BK, Sharp FR. Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex. Eur J Neurosci. 2000 Apr; 12(4):1420-30. PMID: 10762370.
      Citations: 24     Fields:    Translation:AnimalsCells
    34. Tolliver BK, Newman AH, Katz JL, Ho LB, Fox LM, Hsu K, Berger SP, Tolliver BK, Newman AH, Katz JL, Ho LB, Fox LM, Hsu K, Berger SP. Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo. J Pharmacol Exp Ther. 1999 Apr; 289(1):110-22. PMID: 10086994.
      Citations: 7     Fields:    Translation:Animals
    35. Tolliver BK, Ho LB, Fox LM, Berger SP, Tolliver BK, Ho LB, Fox LM, Berger SP. Necessary role for ventral tegmental area adenylate cyclase and protein kinase A in induction of behavioral sensitization to intraventral tegmental area amphetamine. J Pharmacol Exp Ther. 1999 Apr; 289(1):38-47. PMID: 10086985.
      Citations: 6     Fields:    Translation:AnimalsCells
    36. Reid MS, Ho LB, Tolliver BK, Wolkowitz OM, Berger SP, Reid MS, Ho LB, Tolliver BK, Wolkowitz OM, Berger SP. Partial reversal of stress-induced behavioral sensitization to amphetamine following metyrapone treatment. Brain Res. 1998 Feb 02; 783(1):133-42. PMID: 9479062.
      Citations: 9     Fields:    Translation:Animals
    37. Tolliver BK, Ho LB, Reid MS, Berger SP, Tolliver BK, Ho LB, Reid MS, Berger SP. Evidence for dissociable mechanisms of amphetamine- and stress-induced behavioral sensitization: effects of MK-801 and haloperidol pretreatment. Psychopharmacology (Berl). 1996 Aug; 126(3):191-8. PMID: 8876018.
      Citations: 3     Fields:    Translation:Animals
    38. Tolliver BK, Ho LB, Reid MS, Berger SP, Tolliver BK, Ho LB, Reid MS, Berger SP. Evidence for involvement of ventral tegmental area cyclic AMP systems in behavioral sensitization to psychostimulants. J Pharmacol Exp Ther. 1996 Jul; 278(1):411-20. PMID: 8764377.
      Citations: 5     Fields:    Translation:Animals
    39. Reid MS, Hsu K, Tolliver BK, Crawford CA, Berger SP, Reid MS, Hsu K, Tolliver BK, Crawford CA, Berger SP. Evidence for the involvement of phospholipase A2 mechanisms in the development of stimulant sensitization. J Pharmacol Exp Ther. 1996 Mar; 276(3):1244-56. PMID: 8786557.
      Citations: 5     Fields:    Translation:AnimalsCells
    40. Tolliver BK, Carney JM, Tolliver BK, Carney JM. Locomotor stimulant effects of cocaine and novel cocaine analogs in DBA/2J and C57BL/6J inbred mice. Pharmacol Biochem Behav. 1995 Feb; 50(2):163-9. PMID: 7740054.
      Citations: 4     Fields:    Translation:Animals
    41. Tolliver BK, Belknap JK, Woods WE, Carney JM, Tolliver BK, Belknap JK, Woods WE, Carney JM. Genetic analysis of sensitization and tolerance to cocaine. J Pharmacol Exp Ther. 1994 Sep; 270(3):1230-8. PMID: 7932176.
      Citations: 19     Fields:    Translation:Animals
    42. Tolliver BK, Carney JM, Tolliver BK, Carney JM. Comparison of cocaine and GBR 12935: effects on locomotor activity and stereotypy in two inbred mouse strains. Pharmacol Biochem Behav. 1994 Jul; 48(3):733-9. PMID: 7938129.
      Citations: 14     Fields:    Translation:Animals
    43. Tolliver BK, Carney JM, Tolliver BK, Carney JM. Sensitization to stereotypy in DBA/2J but not C57BL/6J mice with repeated cocaine. Pharmacol Biochem Behav. 1994 May; 48(1):169-73. PMID: 8029287.
      Citations: 10     Fields:    Translation:Animals
    Tolliver's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (223)
    Explore
    _
    Co-Authors (20)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _